EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. 2001

E A Kogan, and A D Korczyn, and R G Virchovsky, and Klimovizky SSh, and T A Treves, and M Y Neufeld
EEG and Epilepsy Unit, Department of Neurology, Tel-Aviv Sourasky Medical Center, Israel.

In this pilot study, we examined the long-term treatment effect of donepezil on the quantitative EEG (qEEG) in 12 Alzheimer's disease patients. The qEEGs of the mean absolute and relative amplitudes of betal, alpha, theta and delta activities were obtained at baseline and during donepezil treatment. Comparisons of awake qEEG prior to and during treatment were performed using a 2-way analysis of variance (ANOVA) with repeated measures. In patients with mild dementia (n = 5), the qEEG analysis showed a significant reduction of the mean absolute theta activity (p = 0.05) by donepezil, particularly in frontal and temporo-parietal areas. In patients with moderate/severe dementia (n = 7), a significant decrease in the mean absolute beta 1 activity (p = 0.02), particularly in the frontal and occipital areas may be attributed to disease progression which was not counteracted by the long-term treatment. The differences in qEEG in patients with different stages of dementia under donepezil treatment may be related to different compensatory capacities due to structural and functional brain disturbances.

UI MeSH Term Description Entries
D007189 Indans Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES. Indanones
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D010880 Piperidines A family of hexahydropyridines.
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077265 Donepezil An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE. 1-Benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine hydrochloride,Aricept,Donepezil Hydrochloride,Donepezilium Oxalate Trihydrate,E 2020,E-2020,E2020,Eranz

Related Publications

E A Kogan, and A D Korczyn, and R G Virchovsky, and Klimovizky SSh, and T A Treves, and M Y Neufeld
January 2002, Neuropsychobiology,
E A Kogan, and A D Korczyn, and R G Virchovsky, and Klimovizky SSh, and T A Treves, and M Y Neufeld
September 1998, Neuroscience letters,
E A Kogan, and A D Korczyn, and R G Virchovsky, and Klimovizky SSh, and T A Treves, and M Y Neufeld
January 1993, Acta neurologica Scandinavica. Supplementum,
E A Kogan, and A D Korczyn, and R G Virchovsky, and Klimovizky SSh, and T A Treves, and M Y Neufeld
September 2018, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society,
E A Kogan, and A D Korczyn, and R G Virchovsky, and Klimovizky SSh, and T A Treves, and M Y Neufeld
June 2004, Lancet (London, England),
E A Kogan, and A D Korczyn, and R G Virchovsky, and Klimovizky SSh, and T A Treves, and M Y Neufeld
July 2012, Journal of neuroimaging : official journal of the American Society of Neuroimaging,
E A Kogan, and A D Korczyn, and R G Virchovsky, and Klimovizky SSh, and T A Treves, and M Y Neufeld
January 2004, Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology,
E A Kogan, and A D Korczyn, and R G Virchovsky, and Klimovizky SSh, and T A Treves, and M Y Neufeld
February 2002, Progress in neuro-psychopharmacology & biological psychiatry,
E A Kogan, and A D Korczyn, and R G Virchovsky, and Klimovizky SSh, and T A Treves, and M Y Neufeld
June 2007, Journal of neurochemistry,
E A Kogan, and A D Korczyn, and R G Virchovsky, and Klimovizky SSh, and T A Treves, and M Y Neufeld
April 2002, Clinical EEG (electroencephalography),
Copied contents to your clipboard!